> The FDA has approved Insmed's orphan drug Iplex for the treatment of severe primary IGF-1 deficiency, which causes stunted growth in children. Insmed's stock has soared as a result. Release
> Schering announced it will sell its 50 percent interest in the German distributor ALK-Scherax Arzneimittel to Danish pharmaceutical company ALK-Abello, which already owns a 50 percent interest in ALK-Scherax Arzneimittel. Release
> Genentech has licensed rights to use ImmunoGen's tumor-activated prodrug (TAP) technology with therapeutic antibodies to an undisclosed target. ImmunoGen will receive $1 million in upfront licensing fees as well as milestones. Release
> Cellartis has raised €8 million for the development of human functional cells. Release
> Oncolytics announced it raised $16.48 million in a private placement. Release
> Pittsburgh-based Diamyd Medical has acquired Nurel Therapeutics. Both companies have therapeutic areas that are focused on the treatment of diabetes. Release
And Finally... In the battle to increase prescription drug sales, sales reps are hampered by the inability to reach physicians. Release